Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Angelo who wrote (659)	8/31/1999 3:50:00 PM
From: dch	Respond to of 1494

>> Can any body give me a good reason for buying NTII without hyping. << No. If you buy it, you should definitely hype it.

To: Angelo who wrote (659)	8/31/1999 5:31:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

Angelo, All you have to do is some research on the company and memantine and you'll find plenty of reasons to buy. Memantine is being developed for large underserved markets; Alzheimers, AIDS dementia, Neuropathic Pain. It has completed significant clinical testing with excellent results. It is nearing completion of pivotal testing for Alzheimers dementia and possibly for AIDS dementia. Memantine has a history of use in humans with an excellent safety record (keep in mind that most drugs fail clinicals because of safety reasons). NDA submission should occur next year. There are good reasons to believe that an agreement with a major pharmaceutical company for the marketing of memantine should be signed by the end of the year. These are all excellent reasons to invest in the company. But, add to that the fact that NTII has a market valuation of only $10MM, and no hype should be required to see that this is a value investment in a markedly undervalued company. Name one other company with such promising late stage development projects that has a maket value anywhere near NTII's. As part of your research, take a look at the posts on this thread over this year and go to the site memantine.com for extensive scientific and clinical research on memantine. If you have access, you should look at Harry Tracy's (Neuroinvest) newsletter write ups regarding NTII. neuroinvestment.com Best regards John de C